• ResMed has announced it will open a new distribution center in Greenwood, Indiana, scheduled to begin operations in 2027 to expand its U.S. footprint and strengthen distribution capacity across North America.
• The Greenwood hub is expected to lift two-day transit coverage across North America from 75% to 90% and cut delivery times to Canada by a full day, underscoring how logistics investments can materially influence service levels in medical device supply chains.
• Now we’ll examine how this new Greenwood logistics hub, and its impact on two-day delivery coverage, affects ResMed’s investment narrative.

AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

ResMed Investment Narrative Recap

To own ResMed, you need to believe its sleep and respiratory platform can keep converting diagnosis and awareness into long-term device and software usage, despite reimbursement and competitive pressures. The Greenwood distribution center improves two-day delivery coverage, but does not fundamentally change near term catalysts, which still center on how resilient pricing and margins are if payers tighten, and how much share ResMed can hold against alternative therapies and competing sleep solutions.

The Greenwood hub fits neatly beside ResMed’s ongoing optimization in procurement, manufacturing and logistics, which analysts already see as a key margin driver. By linking coastal operations and raising two-day transit coverage from 75% to 90%, this move adds operational support to that efficiency story, even if its impact is incremental relative to bigger levers like device innovation and expansion of the diagnosis to treatment funnel.

However, against these positives, investors should also be aware of the risk that tighter reimbursement or renewed competitive bidding could...

ResMed's narrative projects $6.4 billion revenue and $1.9 billion earnings by 2028. This requires 7.8% yearly revenue growth and a roughly $0.5 billion earnings increase from $1.4 billion today.

Uncover how ResMed's forecasts yield a $297.47 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Eight fair value estimates from the Simply Wall St Community span roughly US$180 to US$297 per share, showing how far apart individual assessments of ResMed can be. You see this range playing out against a backdrop where logistics and manufacturing improvements are one of the main potential supports for margins and overall performance, so it is worth weighing several different views before deciding how this fits your portfolio.

Explore 8 other fair value estimates on ResMed - why the stock might be worth 29% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your ResMed research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free ResMed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ResMed's overall financial health at a glance.

Ready For A Different Approach?

Our top stock finds are flying under the radar-for now. Get in early:

• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• Uncover the next big thing with 30 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.